The role of cytochrome P450 2D6 in the metabolism of moclobemide

  title={The role of cytochrome P450 2D6 in the metabolism of moclobemide},
  author={Sebastian H{\"a}rtter and Jasper Dingemanse and Dieter Baier and G. Ziegler and Christoph Hiemke},
  journal={European Neuropsychopharmacology},
The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Absorption and disposition parameters were not different between PM and EM. Concurrent application of dextromethorphan, a selective substrate of CYP2D6, did not affect… Expand
P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6
P-gp appears to be a factor in the uptake of dextromethorphan into the mouse brain, and abcb1-polymorphisms need to be considered for CYP2D6 phenotyping experiments with this drug. Expand
Metabolism of Monoamine Oxidase Inhibitors
Preliminary results indicate that several of the MAOIs mentioned above are substrates and/or inhibitors of various cytochrome P450 (CYP) enzymes, which may result in pharmacokinetic interactions with some coadministered drugs. Expand
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
Moclobemide increased plasma concentrations of almotriptan on average by 37%, but the combined administration of these two compounds was well tolerated, and the degree of interaction was much less than that seen previously for sumatriptan or zolmitriptan given with moclobEMide. Expand
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
The benzamide moclobemide's evolution, pharmacodynamic and pharmacokinetic properties are focused on, including the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. Expand
Metabolism of Psychotropic Drugs
In this chapter, specific metabolism of antidepressant and antipsychotic drugs is presented for the main CYP enzymes CYP2D6, CyP2C19, CYP 2C9, and CYP1A2 and the impact of genetic polymorphisms in these enzymes is pointed out. Expand
The clinical role of genetic polymorphisms in drug-metabolizing enzymes
Current evidence suggests that taking genetically determined metabolic capacities of DMEs into account has the potential to improve individual risk/benefit relationship, however, more prospective studies with clinical endpoints are needed before the paradigm of ‘personalized medicine’ based on DME variants can be established. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Monoamine oxidase inhibitors
The monoamine oxidase inhibitors (MAOIs) have been in clinical use for five decades. The coincidental discovery that inhibiting brain monoamine oxidase resulted in antidepressant benefits indirectlyExpand
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions. Expand
Unimolecular and Bimolecular Binding System for the Prediction of CYP2D6-Mediated Metabolism
Validation of this template system with the use of both good and poor CYP2D6 substrates indicated clear advantages of the present system as a tool for drug modification, in addition to enabling highly accurate estimation of the site of metabolism. Expand


Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide
Moclobemide is an example of a reversible MAO-A inhibitor which has been extensively studied and whose pharmacokinetic, clinical pharmacological and toxicological profiles have been thoroughly defined, and has an excellent tolerability profile both within the therapeutic dose range and in overdose. Expand
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *
A combined mephenytoin, sparteine, and caffeine test performed before, during, and after multiple dosing of moclobemide showed changes in the metabolic indexes compatible with a reversible inhibition of oxidation by way of the corresponding CYP enzymes—CYP2C19, CYP2D6, and CYP1A2—during moclOBemide treatment. Expand
The role of individual human cytochromes P450 in drug metabolism and clinical response.
The molecular basis of this deficiency is now well understood and methods for the detection of poor metabolizers are discussed, as well as the effect of the polymorphism on drug metabolism. Expand
Biotransformation of moclobemide in humans
The structure of the urinary metabolites formed after moclobemide administration in humans was elucidated, and the pattern compared with that in the plasma was found to be qualitatively but not quantitatively similar to that observed in urine. Expand
An update of recent moclobemide interaction data
  • J. Dingemanse
  • Chemistry, Medicine
  • International clinical psychopharmacology
  • 1993
In combination with therapeutic doses of either fluvoxamine or fluoxetine, moclobemide did not provide any indication of a serotoninergic syndrome, so that no wash-out period is needed when switching from a selective serotonin re-uptake inhibitor to moclOBemide or vice versa. Expand
The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
1. The enzyme kinetics of dextromethorphan O-demethylation in liver microsomes from three extensive metabolisers (EM) with respect to CYP2D6 indicated high (Km1 2.2-9.4 microM) and low (Km2Expand
Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine
No deviations of moclobemide pharmacokinetics should be expected in poor metabolizers of debrisoquine compared with normal metabolizers, and this was true for both single and multiple dosing. Expand
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
The neurochemical profile of moclobemide indicates clearly that this nonhydrazine nonhepatotoxic MAO-A inhibitor represents a novel and safe drug for treatment of affective disorders. Expand
Human cytochromes P450: problems and prospects.
  • F. Gonzalez
  • Biology, Medicine
  • Trends in pharmacological sciences
  • 1992
Human P450-based in vitro systems are being developed to evaluate drug and carcinogen metabolism, and a large degree of inter- and intra-species variability in regulation and catalytic activities is suggested. Expand
Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care.
Recent work indicating that genetically determined differences in hepatic isoenzyme function can be risk factors in the development of a variety of diseases is reviewed and the possible implications of this work relative to the long-term use of SSRIs will be discussed. Expand